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Despite growing evidence that increased brain-derived neurotrophic factor (BDNF) and hippocampal adult
neurogenesis are necessary for the behavioral actions of antidepressants in rodents, the cellularmechanisms
involved in these effects are still unknown. Li et al. in this issue of Neuron demonstrate that the presence
of TrkB, the high-affinity receptor for BDNF, in hippocampal neural progenitor cells is required for the neuro-
genic and behavioral actions of antidepressant treatments.Although pharmacological treatments for
major depressive illness, which afflicts
17% of the population in the USA alone,
have been available for over 50 years,
the molecular mechanisms underlying
the therapeutic response to these agents
have remained unresolved. Available
medications are known to block the reup-
take or breakdown of serotonin, norepi-
nephrine, or both in brain, but elevation
of these monoamines, which occurs
rapidly (within days), does not explain
the time lag of weeks to months that is
required for a therapeutic response to
antidepressant treatment.
The discovery that long-term antide-
pressant treatment increases brain-de-
rived neurotrophic factor (BDNF), a major
neurotrophin in the brain, has offered an
alternative to the monoamine hypothesis
of depression and antidepressant re-
sponse (Duman et al., 1997). The finding
that antidepressants also increase hippo-
campal neurogenesis extended this work
and gave birth to the hypothesis that this
cellular form of neuroplasticity in the adult
brain is necessary for the behavioral ef-
fects of antidepressants (Drew and Hen,
2007; Duman and Monteggia, 2006).
These findings, as well as reports that
both BDNF expression and hippocampal
neurogenesis are decreased in animal
models of depression, have raised several
fundamental questions. Are these effects
causally related (i.e., does induction of
BDNF underlie the increase in neurogene-
sis) or are they merely coincidental, unre-
lated responses? Do increased BDNF
and hippocampal neurogenesis contrib-
ute to the behavioral actions of antide-
pressants, and conversely, does reduc-tion of these processes contribute to
depression? An article by Li et al. in this
issue of Neuron (Li et al., 2008) elegantly
demonstrates a direct functional link
between these two key areas of investiga-
tion, highlighting the importance of TrkB
and adult neurogenesis in the efficacy
of antidepressants in rodent behavioral
models.
One fundamental question of the
current study concerns the cellular locali-
zation of TrkB and how this influences
antidepressant regulation of adult neuro-
genesis. Toward this end the Parada
laboratory developed and utilized state-
of-the-art cell isolation and labeling
approaches in combination with sophisti-
cated TrkB mutant mouse models that
take advantage of the expression of cell-
specific antigens. In the adult hippocam-
pus,neural progenitor cells (NPCs) located
in the subgranular zone proliferate and
give rise to immature neurons that
migrate into the granule cell layer, where
theydifferentiate andmature (seeFigure1)
(Zhao et al., 2008). These cells express the
markers Nestin and glial-fibrillary acidic
protein (GFAP). Li andcolleaguesusefluo-
rescence-activated cell sorting (FACS) to
isolate NPCs from Nestin-GFP transgenic
mice and show that adult hippocampal
progenitor cells express TrkB as well as
BDNF. They also demonstrate that TrkB
is expressed on dividing progenitor cells,
as determined by colocalization with
a cell-cycle marker, as well as on imma-
ture andmature neurons in brain sections.
Because there are two major types of
NPCs, slowly dividing/quiescent neural
progenitors (QNP) and rapidly amplifying
neural progenitors (ANP), both of whichNeuron 5express Nestin, a remaining issue is
whether one or both cell types express
TrkB. This is important to define because
one study has reported that chronic
administration of the antidepressant flu-
oxetine or Prozac stimulates the prolifera-
tion of ANP, but not QNP, cells (Encinas
et al., 2006), while another study has
found that electoconvulsive seizure,
which is still the most efficacious treat-
ment for depression, increases both types
of NPCs (Nishida et al., 2008).
To directly test the functional signifi-
cance of TrkB expressed in NPCs, Li and
colleagues generated trkB gene deletion
mutants in a cell-specific manner. Condi-
tional mutants were generated by cross-
ing mice harboring the trkB floxed allele
with transgenic mice expressing Cre
recombinase under the human GFAP
(hGFAP) promoter. Because TrkB is also
expressed on mature neurons, deletion
of TrkB in this population of cells was
also generated by crossing these mice
with another line where Cre expression is
under the control of the promoter for Syn-
apsin I (Syn), a marker of mature neurons.
At a gross structural level, the TrkBhGFAP,
but not the TrkBSyn, deletion mutants
exhibited a reduction in the volume of
the hippocampus as early as postnatal
day 10. This effect was due to a reduction
in the number of granule cells, and was
not observed in other brain regions such
as the striatum. These findings highlight
the importance of NPC-expressed TrkB
on early postnatal development of the
hippocampus.
Direct analysis of adult hippocampal
neurogenesis revealed that the TrkBhGFAP
mutant mice exhibited a dramatic (greater9, August 14, 2008 ª2008 Elsevier Inc. 349
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Previewsthan 50%) reduction in basal levels of cell
proliferation that was not observed in the
TrkBSyn deletion mutants. BDNF stimula-
tion of neurosphere size was also blocked
in cultures isolated from TrkBhGFAP mice.
Importantly, the ability of chronic adminis-
tration of either a serotonin selective
reuptake inhibitor (fluoxetine) or a tricyclic
antidepressant (imipramine) to increase
cell proliferation was completely blocked
in the TrkBhGFAP mice. In contrast, there
was no significant effect in the TrkBSyn
mice. In addition, the induction of cell
proliferation by exercise, which also pro-
duces antidepressant effects in rodent
models and in humans, was also blocked
in the TrkBhGFAP mice.
Despite previous studies demonstrat-
ing that BDNF infusions increase neuro-
genesis and that induction of neurogene-
sis is blocked in BDNF heterozygous
deletion mutants, there have also been
conflicting reports (Drew and Hen, 2007;
Duman and Monteggia, 2006; Monteggia
et al., 2007). In particular, one study has
reported that expression of a dominant-
negative mutant of TrkB in transgenic
mice did not influence basal or antide-
pressant-induced cell proliferation, al-
though a decrease in the survival of new-
born neurons was observed (Sairanen
et al., 2005). This discrepancy is likely
due to expression of the TrkB dominant-
negative mutant in neurons, under the
control of the Thy1 promoter. Given this
finding, it would be interesting to deter-
mine if survival of new neurons is de-
creased in theTrkBSynmutantmice. These
inconsistencies and discrepancies under-
score the significance of the current
study, as it provides the first evidence
that the neurogenic actions of BDNF and
antidepressants are mediated by TrkB
receptors located on NPCs.
Another key aspect of these current
data is the functional link between
BDNF-TrkB, neurogenesis, and the be-
havioral actions of antidepressant. Previ-
ous studies have reported that the
behavioral responses to antidepressants
are blocked in BDNF deletion mutant
mice (Duman and Monteggia, 2006). In
addition, there is strong evidence that
blockade of adult neurogenesis by cell-
cycle inhibitors or irradiation blocks the
behavioral actions of antidepressants,
though there are some exceptions (Drew
and Hen, 2007). The results of the current
study directly link BDNF-TrkB signaling,
adult neurogenesis, and antidepressant-
regulated behaviors: the effects of fluoxe-
tine or imipramine, as well as exercise
in two different behavioral models, the
novelty-suppressed feeding test (NSFT)
and the tail suspension test (TST), are
completely blocked in the TrkBhGFAP mice,
but once again not in the TrkBSyn deletion
mutants. The significance of these results
lies not only in the connection between
antidepressant behavioral responses and
TrkB, but also between these responses
and adult neurogenesis.
Nevertheless, there are also some limi-
tations of these behavioral paradigms.
First, the TST is a behavioral despair
model that was designed as a rapid
screen for antidepressants, which in-
crease the amount of time of a mouse
will struggle before becoming immobile
or giving up. Although the current study
tests the influence of long-term antide-
pressant treatment, the fact remains that
this test responds to acute drug adminis-
tration, limiting its clinical relevance given
the time lag for a therapeutic response to
antidepressant treatment. Second, the
NSFT is actually a model of anxiety, but
the response is dependent on chronic an-
tidepressant treatment, which decreases
the latency to feed in an open field. The
impact of the current study will be further
increased by analysis of TrkB deletion in
other behavioral tests, such as chronic
mild stress-induced anhedonia (stress de-
creases sucrose consumption) or social
defeat (exposure to dominant resident de-
creases social interaction), both of which
measure core symptoms of depression
that are reversedby long-termantidepres-
sant administration.
Even though this study of the TrkBhGFAP
and TrkBSyn mice indicates that the neu-
rogenic and behavioral actions of antide-
pressants are mediated by direct effects
on NPCs, the early postnatal develop-
mental changes in the hippocampus of
the TrkBhGFAP mice raise the possibility
that the effects are not directly related to
TrkB in adult NPCs. Specifically, the
decrease in the number of granule cells
and NPCs could account for the neuro-
genic and behavioral effects observed in
the adult animals. To address this issue,
the Parada laboratory generated a third
line of TrkB deletion mutant mice using
a tamoxifen-inducible form of Cre re-
combinase under the Nestin promoter
(TrkBNestin). This powerful, complemen-
tary line allows inducible deletion of TrkB
in the NPCs, both QNP and ANP, but
Figure 1. Schematic Diagram Summarizing the Cellular Actions of BDNF-TrkB Signaling in
the Neurogenic and Behavioral Responses to Antidepressants
The study by Li et al. in this issue of Neuron demonstrates that conditional deletion of TrkB in GFAP-pos-
itive or Nestin-positive neural progenitor cells blocks the neurogenic and behavioral actions of antidepres-
sant treatment and exercise. In contrast, deletion of TrkB in mature, Synapsin-positive neurons does not
influence these responses. Additional studies will be required to determine if BDNF is released from the
neural progenitor cells or from mature neurons. QNP, quiescent neural progenitor; ANP, amplifying neural
progenitor.350 Neuron 59, August 14, 2008 ª2008 Elsevier Inc.
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Previewsonly in the adult hippocampus. Like the
TrkBhGFAP line, there was a complete
blockade of antidepressant-induced cell
proliferation in the TrkBNestin mice, but
without a decrease in hippocampal vol-
ume or thickness of the granule cell layer
that is observed in the TrkBhGFAP mice.
There was also a decrease in basal neuro-
genesis levels in the TrkBNestin mice, but
this effect was more subtle (30%) than
in the TrkBhGFAP mice, presumably due
to the lack of developmental effects.
Notably, the behavioral effects of antide-
pressant treatment and exercise were
also completely blocked in the TrkBNestin
mice.
As is often the case, elegant studies
such as the current report raise additional
questions. One issue that remains unre-
solved is the source of BDNF that is
regulated by antidepressant treatment or
exercise. The current study presents evi-
dence that BDNF, like TrkB, comes from
the NPCs. BDNF is expressed in the
FACS-isolated NPCs, and BDNFhGFAP de-
letion mutant mice also display a reduc-
tion in the volume of dentate gyrus graule
cell layer, as seen in the TrkBhGFAP mice
(although additional studies are needed
to determine if there is a decrease in neu-
rogenesis in the BDNFhGFAP mice). The
authors suggest that these results sup-
port a cell-autonomous effect of BDNF-
TrkB signaling in the actions of antide-
pressant treatment and exercise on NPC
proliferation (see Figure 1). However, it is
also possible that in the adult animal,
BDNF is released from mature neurons
or even glia in response to antidepressant
treatment or exercise. Indeed, previous
studies have demonstrated that these
treatments induce BDNF expression in
mature neurons in the granule cell layer
(Duman and Monteggia, 2006). Additional
studies using cell-specific deletion ap-
proaches similar to those used for condi-
tional deletion of TrkB will be required to
further elucidate the source of BDNF.
Another, related question is which mono-
amine receptor subtype or subtypes
mediate antidepressant stimulation of
BDNF-TrkB signaling.
Another question raised by the current
study, as well as previous reports, iswhether reductions in BDNF-TrkB signal-
ing and neurogenesis contribute to a de-
pressive-like behavioral phenotype. In
the current study, significant reductions
in basal neurogenesis in the TrkBhGFAP
and TrkBNestin mice were not accompa-
nied by increased immobility in the TST
or latency in the NSFT. Similarly, ablation
of cell proliferation by focused irradiation
blocks antidepressant induction of neuro-
genesis and behavior, but does not result
in depressive-like behaviors (Airan et al.,
2007; Santarelli et al., 2003). Together
these findings indicate that while induc-
tion of BDNF-TrkB signaling and neuro-
genesis is required for the behavioral
actions of antidepressants, reductions of
these processes are not sufficient to pro-
duce depressive-like behaviors. How-
ever, a note of caution is necessary as
these behavioral tests, particularly the
TST, were designed to screen for antide-
pressant responses, not as models of de-
pression. Another possibility is that there
may be a gene 3 environment interaction
(i.e., prior exposure to stress could lead to
a behavioral vulnerability in the TrkBhGFAP
or TrkBNestin mice), as reported for BDNF
mutant mice and for a functional BDNF
polymorphism in humans (Duman et al.,
2007; Kim et al., 2007).
In addition to BDNF-TrkB, antidepres-
sant treatments also increase the expres-
sion of other growth factors (Duman and
Monteggia, 2006), and a recent study
reported that one of these, vascular
endothelial growth factor (VEGF), is also
required for the neurogenic and behavi-
oral actions of antidepressants (Warner-
Schmidt and Duman, 2007). These find-
ings suggest that there may be redundant
or overlapping growth factor signaling
pathways that underlie the induction of
neurogenesis and behavioral responses
to antidepressants, and raise still addi-
tional questions. How do these trophic
factors interact? Do they share the same
intracellular signaling pathways? Or does
signaling through one factor (e.g., BDNF-
TrkB) influence expression, trafficking,
and/or signaling of other receptors?
Despite these issues, the current study
provides a major advance in our under-
standing of the cellular actions of antide-Neuron 5pressant treatment by demonstrating
that TrkB on neural progenitors in the hip-
pocampus is a common molecular target
for both chemical agents and exercise.
With further advances in our knowledge
of the cellular mechanisms that regulate
neurogenesis, and with the development
of tools targeting these mechanisms,
studies of these ‘‘old’’ drugs that were
once thought to merely counteract chem-
ical imbalances will continue to surprise
us and lead to discoveries that can be
targeted for novel treatments for mood
disorders.
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